Get the Stockscreener App
0.7301
0.67%
-0.0049
After Hours:
.73
-0.000100
-0.01%
Avenue Therapeutics Inc stock is traded at $0.7301, with a volume of 252.
It is down -0.67% in the last 24 hours and down -0.67% over the past month.
See More
Previous Close:
$0.735
Open:
$0.7301
24h Volume:
252
Relative Volume:
0.47
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-0.1916
EPS:
-3.81
Net Cash Flow:
$-12.45M
1W Performance:
-0.67%
1M Performance:
-0.67%
6M Performance:
-83.79%
1Y Performance:
-96.88%
1-Day Range:
$0.7301
$0.7301
1-Week Range:
$0.7301
$0.7301
52-Week Range:
$0.5231
$0.735
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare ATXI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.7301 | 0 | 0 | -10.38M | -12.45M | -3.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Avenue Therapeutics Inc Stock (ATXI) Latest News
Head to Head Survey: Avenue Therapeutics (NASDAQ:ATXI) vs. Neoleukin Therapeutics (NASDAQ:NLTX) - Defense World
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million - The Manila Times
Avenue Therapeutics (NASDAQ:ATXI) vs. ADVANZ PHARMA (OTCMKTS:CXRXF) Financial Analysis - Defense World
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million - The Manila Times
Apogee Therapeutics, Inc. Announces Closing of Public - GlobeNewswire
Avenue Therapeutics, Inc. (ATXI) stock price, news, quote and history - Yahoo
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewswire
United States Drug Resistant Epilepsy Market 2025 | Industry Developments, Future Growth, Share & Industry Insights - openPR.com
Operating cash flow per share of Avenue Therapeutics, Inc. – LSX:A40BWJ - TradingView
Ceapro (OTCMKTS:CRPOF) and Avenue Therapeutics (NASDAQ:ATXI) Financial Contrast - Defense World
Affiliate of Pacific Avenue Capital Partners Completes the Acquisition of Pick Your Part from LKQ Corporation - Shreveport Times
Park Avenue Securities LLC Has $212,000 Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - Defense World
United Therapeutics Corporation $UTHR Stake Lifted by Park Avenue Securities LLC - Defense World
2,085 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Park Avenue Securities LLC - Defense World
Park Avenue Securities LLC Has $622,000 Stock Position in Halozyme Therapeutics, Inc. $HALO - Defense World
Novo Nordisk A/S (NVO) Attracts Park Avenue Securities Investment - Yahoo Finance
Postoperative Pain Management Market to Expand Significantly by 2032, States DelveInsight Report - openPR.com
SpringWorks Therapeutics Inc.’s volatility index tracking explainedEarnings Overview Summary & Stock Portfolio Risk Management - newser.com
How hedge fund analytics apply to Janux Therapeutics Inc. stockWeekly Profit Summary & AI Optimized Trade Strategies - newser.com
Is TScan Therapeutics Inc. meeting your algorithmic filter criteria2025 Valuation Update & Safe Capital Growth Tips - newser.com
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol - IT Business Net
7 Biotech Stocks Trading At 52-Week HighsCan The Rally Continue? - RTTNews
Beam Therapeutics (NASDAQ:BEAM) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Nasdaq Compliance and Long-Term Viability of Society Pass (SOPA) - AInvest
Neurology biopharmas rebound on trial catalysts and Q2 gains - BioWorld MedTech
Dietary Changes Could Provide a Therapeutic Avenue for Brain Cancer | Newswise - Newswise
Coya Therapeutics to Participate at Upcoming September 2025 Investor Conferences - biospace.com
Coya Therapeutics to Participate at Upcoming September Investor Conferences - Stock Titan
How to escape a deep drawdown in Bicara Therapeutics Inc.Weekly Investment Report & Entry Point Strategy Guides - Newser
FBIO In FocusWill CUTX-101 Make History As The First FDA-Approved Menkes Disease Therapy? - RTTNews
Plus Therapeutics Inc. stock trend forecastPortfolio Return Summary & Fast Gaining Stock Strategy Reports - Newser
Abeona Therapeutics to expand in Midtown - NEO-Trans.blog
Applied Therapeutics Inc. (NASDAQ:APLT) Receives $6.10 Average PT from Analysts - MarketBeat
Has Anika Therapeutics Inc. formed a bullish divergenceJuly 2025 Macro Moves & Weekly High Return Stock Forecasts - Newser
Will Galectin Therapeutics Inc. stock recover after recent dropJuly 2025 Breakouts & High Conviction Trade Alerts - Newser
Avenue Therapeutics Reports Positive Earnings Amid Challenges - TipRanks
North American Morning Briefing : Stock Futures -2- - MarketScreener
Should you wait for a breakout in Plus Therapeutics Inc.Quarterly Portfolio Report & Real-Time Buy Zone Alerts - Newser
Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN) - MSN
XTX Topco Ltd Buys 68,245 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Clear Street reiterates Buy rating on Beam Therapeutics stock at $34 - Investing.com Canada
Abeona Therapeutics Amends Loan Agreement with Avenue - The Globe and Mail
Stoke Therapeutics Inc. Stock Analysis and ForecastFree Investment Risk Control - jammulinksnews.com
Abeona Therapeutics lowers loan interest rate and issues warrants in loan amendment - Investing.com
Postoperative Pain Management Market to Expand Significantly - openPR.com
Why Acrivon Therapeutics Inc. stock attracts strong analyst attentionExpert Backed Predictions - Newser
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know - MSN
112-employee biotech leaves Cambridge HQ for Watertown - The Business Journals
AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion - The Wall Street Journal
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.50%
Cap:
|
Volume (24h):